Logotype for UCB SA

UCB (UCB) investor relations material

UCB Jefferies Global Healthcare Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for UCB SA
Jefferies Global Healthcare Conference summary17 Nov, 2026

Portfolio growth and business development

  • BIMZELX patent protection runs to 2037; four additional growth drivers have patents into the early 2030s, supporting a growth agenda underway for two years.

  • Current assets could support growth after 2035 if successful; external additions in familiar disease areas can strengthen internal pillars and diversify long-term pipeline risk.

  • 2026 and likely 2027 focus remains on executing launches, while IMIDomics, Antengene, Neurona and Candid add early-stage capabilities and modalities in established therapeutic areas.

  • Business development is shifting toward disease biology and longer-term benefit, including cell therapy for severe epilepsy and T-cell engagers aimed at immune reset in autoimmune disease.

BIMZELX outlook

  • Management sees potential for at least EUR 7bn in peak sales, citing superiority versus four competitors across psoriasis and psoriatic arthritis, and 150,000 patients with strong treatment experience.

  • Broader uptake may take time as prescribing habits, guidelines, PBM rebates and step edits do not always reward clinical superiority; management expects these barriers to ease over time.

  • Management sees potential across psoriasis, psoriatic arthritis and hidradenitis suppurativa; HS is an early-stage opportunity with compelling data and a growing market.

  • HS assessment should account for standard-of-care comparison, efficacy criteria, disease severity, placebo response and antibiotic use in trials.

  • HS diagnosis averages seven years after symptoms; management aims for earlier treatment and expects market leadership based on its data.

Neurology and pipeline differentiation

  • Myasthenia gravis is a larger, specialty market than previously understood, with varied prescribing practices and uneven uptake of anti-FcRn and anti-C5 therapies across geographies and hospitals.

  • The portfolio includes one anti-FcRn and one anti-C5, enabling treatment choice by patient profile; potential BCMA x CD3 T-cell engagers could add options for patients with high IgG levels.

  • Neurona cell therapy targets very severe temporal lobe epilepsy, including patients who cannot access surgery, with the aim of reducing seizures and supporting cognitive and brain development.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next UCB earnings date

Logotype for UCB SA
H2 202625 Feb, 2027
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next UCB earnings date

Logotype for UCB SA
H2 202625 Feb, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

UCB SA is a global biopharmaceutical company specializing in the discovery and development of innovative medicines and solutions for severe neurological and immunological disorders. The company's main areas of focus include treatments for conditions such as epilepsy, Parkinson's disease, and various immunological diseases. UCB operates through its biopharmaceutical segment, which develops, manufactures, and markets these therapies. The company is headquartered in Brussels, Belgium, and its shares are listed on the Euronext Brussels.